Search results for "liver injury"

showing 10 items of 144 documents

Rivaroxaban-induced hepatotoxicity

2017

Aim/Objective/Background Direct-acting oral anticoagulant drugs are marketed worldwide for the primary and secondary prevention and treatment of thromboembolic disorders. Rivaroxaban, an oral, direct factor Xa inhibitor, is one of the most used. Rivaroxaban-induced hepatotoxicity is unusual, although a number of adverse reports have recently been reported. Here, we report two new cases of rivaroxaban-induced hepatitis. Methods A systematic search of case reports on the MEDLINE database encompassing the years 2008–2016 was carried out.Additional references were obtained following a manual search of the retrieved papers. We report two new cases of adverse events occurred in patients treated w…

Malemedicine.medical_specialtySettore MED/09 - Medicina Internamedicine.drug_mechanism_of_actionFactor Xa InhibitorMEDLINE030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineRivaroxabanInternal medicinemedicineHumansAgedAged 80 and overSecondary preventionRivaroxabanHepatologybusiness.industryGastroenterologydrug-induced liver injury hepatotoxicity pharmacovigilancerivaroxabanOral anticoagulantFemale030211 gastroenterology & hepatologyChemical and Drug Induced Liver InjurybusinessFactor Xa Inhibitorsmedicine.drugEuropean Journal of Gastroenterology & Hepatology
researchProduct

Analysis of metabolic and gene expression changes after hydrodynamic DNA injection into mouse liver.

2011

The hydrodynamic injection in mice tail vein of a plasmid (40 mg DNA) bearing the human a1-antitrypsin gene mediates: a) good liver gene transfer resulting in therapeutic plasma levels of human protein (1 mg/ml, approximately) from days 1—10 after injection; b) low liver injury as demonstrated by a poor and transient increase of aspartate aminotransferase (AST) and alanine transaminase (ALT) in mouse plasma; 3) limited expression and metabolic changes in host liver genes and metabolites as evaluated on days 2 and 10 after injection. Groups of three mice were uninjected (control) or hydrodynamically injected with saline or plasmid DNA and then sacrificed on days 2 and 10 after injection. The…

Microarraymedicine.medical_treatmentProtein Array AnalysisPharmaceutical Sciencechemistry.chemical_compoundMicePlasmidGene expressionmedicineAnimalsHumansTransgenesSalineGenePharmacologyLiver injurybiologyGene Transfer TechniquesGeneral MedicineDNAmedicine.diseaseMolecular biologyMice Inbred C57BLAlanine transaminasechemistryGene Expression RegulationLiveralpha 1-Antitrypsinbiology.proteinDNAPlasmidsBiologicalpharmaceutical bulletin
researchProduct

Safety of a 3-weekly schedule of carboplatin plus pegylated liposomal doxorubicin as first line chemotherapy in patients with ovarian cancer: prelimi…

2006

Abstract Background The MITO-2 (Multicentre Italian Trials in Ovarian cancer) study is a randomized phase III trial comparing carboplatin plus paclitaxel to carboplatin plus pegylated liposomal doxorubicin in first-line chemotherapy of patients with ovarian cancer. Due to the paucity of published phase I data on the 3-weekly experimental schedule used, an early safety analysis was planned. Methods Patients with ovarian cancer (stage Ic-IV), aged 2, every 3 weeks or to carboplatin AUC 5 plus pegylated liposomal doxorubicin 30 mg/m2, every 3 weeks. Treatment was planned for 6 cycles. Toxicity was coded according to the NCI-CTC version 2.0. Results The pre-planned safety analysis was performed…

OncologyCancer Researchendocrine system diseasesSettore MED/06 - Oncologia Medicamedicine.medical_treatmentPACLITAXELlaw.inventionPolyethylene Glycolschemistry.chemical_compoundRandomized controlled trialSTAGE-IIIlawCYCLOPHOSPHAMIDEAntineoplastic Combined Chemotherapy ProtocolsOvarian NeoplasmsSTERICALLY STABILIZED LIPOSOMESMiddle Agedlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensCombined Modality Therapyfemale genital diseases and pregnancy complicationsPaclitaxelOncologyMITO-2 randomized trialcarboplatinSURVIVALFemaleChemical and Drug Induced Liver Injurymedicine.drugAgranulocytosisResearch ArticleAdultmedicine.medical_specialtyCARCINOMAOvariectomylcsh:RC254-282Drug Administration ScheduleDrug HypersensitivityCISPLATINpreliminary resultInternal medicinemedicineGeneticsXENOGRAFTSHumansDoxorubicinParesthesianeoplasmsMETAANALYSISAgedChemotherapybusiness.industryAlopeciamedicine.diseasePHASE-IIIThrombocytopeniaCarboplatinSurgeryClinical trialchemistryDoxorubicinLiposomesFeasibility StudiesTopotecanOvarian cancerbusinessBMC Cancer
researchProduct

Impairment of PGC-1 Alpha Up-Regulation Enhances Nitrosative Stress in the Liver during Acute Pancreatitis in Obese Mice

2020

Acute pancreatitis is an inflammatory process of the pancreatic tissue that often leads to distant organ dysfunction. Although liver injury is uncommon in acute pancreatitis, obesity is a risk factor for the development of hepatic complications. The aim of this work was to evaluate the role of PGC-1&alpha

PGC-1&#9450301 basic medicineobesitymedicine.medical_specialtyAntioxidantacute pancreatitisPhysiologymedicine.medical_treatmentClinical BiochemistryPGC-1αAlpha (ethology)Nitrosative stressliverHepatic ComplicationBiochemistryArticle03 medical and health sciences0302 clinical medicineDownregulation and upregulationInternal medicinemedicineObesityMolecular BiologyLiver injurybusiness.industrylcsh:RM1-950Organ dysfunctionCell BiologyBiología y Biomedicina / Biologíamedicine.diseasenitrosative stressAcute pancreatitislcsh:Therapeutics. Pharmacology030104 developmental biologyEndocrinologyLiver030220 oncology & carcinogenesisPancreatitisAcute pancreatitismedicine.symptombusinessAntioxidants
researchProduct

Contrasting responses of Kupffer cells and inflammatory mononuclear phagocytes to biliary obstruction in a mouse model of cholestatic liver injury.

2012

Background Biliary obstruction and cholestasis are serious complications of many liver diseases. Although resident hepatic macrophages (Kupffer cells) are frequently implicated in disease progression, most studies fail to differentiate the contribution of Kupffer cells and inflammatory mononuclear phagocytes (iMNPs) that infiltrate the liver subsequent to obstruction. Aim This study was undertaken to examine the roles and potential interactions of these two disparate mononuclear phagocyte populations in hepatic injury attending cholestasis. Methods Female, C57Bl/6 mice were injected with magnetic beads on day 3 prior to sham operation or bile duct ligation (BDL) to facilitate subsequent Kup…

Pathologymedicine.medical_specialtyChemokineLiver cytologyKupffer Cellsmedicine.medical_treatmentInflammationCholestasis IntrahepaticBiologyReal-Time Polymerase Chain Reactiondigestive systemMiceCholestasismedicineAnimalsMononuclear Phagocyte SystemLiver injuryHepatologyKupffer cellMononuclear phagocyte systemmedicine.diseaseFlow CytometrySpecific Pathogen-Free OrganismsMice Inbred C57BLmedicine.anatomical_structureCytokineImmunologybiology.proteinFemalemedicine.symptomLiver international : official journal of the International Association for the Study of the Liver
researchProduct

N-Acetylcysteine for the Management of Non-Acetaminophen Drug-Induced Liver Injury in Adults: A Systematic Review

2022

Introduction: Idiosyncratic drug-induced liver injury (DILI) is a rare adverse reaction to drugs and other xenobiotics. DILI has different grades of severity and may lead to acute liver failure (ALF), for which there is no effective therapy. N-acetylcysteine (NAC) has been occasionally tested for the treatment of non-acetaminophen drug-induced ALF. However, limited evidence for its efficacy and safety is currently available. Our aim was to elucidate the benefit and safety of NAC in DILI and evaluate its hepatoprotective effect.Methods: We conducted a systematic review to evaluate the management and prevention focused on NAC in idiosyncratic DILI. The main outcomes included mortality due to …

PharmacologyPharmacology (medical)DILInon-acetaminophenacute liver failureacute liver injuryN-acetylcysteine
researchProduct

N-Acetylcysteine for Preventing Acetaminophen-Induced Liver Injury: A Comprehensive Review.

2022

Aims: N-Acetylcysteine (NAC) is used as an antidote in acetaminophen (APAP) overdose to prevent and mitigate drug-induced liver injury (DILI). Our objective was to systematically review evidence of the use of NAC as a therapeutic option for APAP overdose and APAP-related DILI in order to define the optimal treatment schedule and timing to start treatment.Methods: Bibliographic databases (PubMed, Web of Science, Embase, and MEDLINE) were searched for retrospective and prospective cohort studies, case series, and clinical trials. The prespecified primary outcomes were DILI-related mortality, hepatotoxicity, and adverse events (AEs).Results: In total, 34 studies of NAC usage in APAP-related DI…

PharmacologysafetyhepatotoxicitySettore MED/09 - Medicina InternaPharmacology (medical)N-acetyl-cysteinedrug-induced liver injuryacetaminophen
researchProduct

A phenobarbital overdose: a case report

2017

Background: Phenobarbital is a long-acting barbiturate, responsible for many cases of poisoning, from unintentional overdose or attempted suicide. We report a case of phenobarbital overdose in a patient with history of depression. Patients and Methods: A 60 year old woman was admitted to our Internal Medicine Unit for drowsiness, irritability, difficulties in the maintenance of an upright position, dysphasia and weakness. She was suffering from depression and epilepsy and treated with phenobarbital 150 mg/die. Results: At the admittance, she had high fever and neck stiffness; phenobarbital serum levels were 71.2 mcg/ml (3 times u.n.l.); aminotransferases were 12-17u.n.l. Arterial blood pres…

Phenobarbital DILI drug-induced liver injurySettore MED/09 - Medicina Interna
researchProduct

Differential Roles of JNK in ConA/GalN and ConA-Induced Liver Injury in Mice

2008

Tumor necrosis factor-alpha-mediated liver injury can be induced by several different means; however, the signaling events and mechanisms of cell death are likely different. We investigated the mechanism of both apoptotic and necrotic hepatocyte cell death as well as the role of c-Jun NH2-terminal kinase (JNK) in the ConA and ConA/D-galactosamine (GalN) models of murine liver injury. ConA alone induced primarily necrotic cell death with no caspase activation, whereas ConA/GalN induced apoptosis in addition to necrotic cell death. The bi-modal death pattern in the ConA/GalN model was confirmed by the use of transgenic mice expressing a dominant-negative form of Fas-associated death domain in…

Programmed cell deathNecrosisFas-Associated Death Domain ProteinApoptosisGalactosamineMitochondria Liverchemical and pharmacologic phenomenaCaspase 8Pathology and Forensic MedicineMiceNecrosisConcanavalin AmedicineAnimalsPhosphorylationDeath domainLiver injuryCaspase 8biologyLiver DiseasesJNK Mitogen-Activated Protein Kinasesmedicine.diseaseMolecular biologyEnzyme ActivationMice Inbred C57BLDisease Models Animalmedicine.anatomical_structureConcanavalin AApoptosisHepatocytebiology.proteinMutant ProteinsChemical and Drug Induced Liver Injurymedicine.symptomGene DeletionRegular ArticlesBH3 Interacting Domain Death Agonist ProteinThe American Journal of Pathology
researchProduct

Factors that influence the quality of metabolomics data in in vitro cell toxicity studies: a systematic survey

2021

Abstract REACH (Registration, Evaluation, Authorization and Restriction of Chemicals) is a global strategy and regulation policy of the EU that aims to improve the protection of human health and the environment through the better and earlier identification of the intrinsic properties of chemical substances. It entered into force on 1st June 2007 (EC 1907/2006). REACH and EU policies plead for the use of robust high-throughput "omic" techniques for the in vitro investigation of the toxicity of chemicals that can provide an estimation of their hazards as well as information regarding the underlying mechanisms of toxicity. In agreement with the 3R’s principles, cultured cells are nowadays wide…

Quality ControlHEPATOTOXICITYSciencemedia_common.quotation_subjectDiseasesComputational biologyMETABOLISMBiologyHEPATOCYTESCitric AcidArticleXenobioticsProductes químicschemistry.chemical_compoundMetabolomicsMedical researchCell Line TumorMetabolomeHumansMetabolomicsSPECTROMETRY DATAQuality (business)HEPARG CELLSAcetaminophenmedia_commonBATCH EFFECT CORRECTIONMultidisciplinaryFATTY-ACIDDrug discoveryValproic AcidQRReproducibility of ResultsHep G2 CellsIn vitroBioactive compoundGLUTAMINEMetabolic pathwayLiverchemistryToxicityMetabolomeMedicineCURRENT STATEChemical and Drug Induced Liver InjuryXenobioticMetabolic Networks and PathwaysBiomarkersVALPROATEScientific Reports
researchProduct